This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Octreotide in gastrointestinal malignancy

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Octreotide therapy has been shown to prolong survival in patients with advanced, chemotherapy-resistant gastrointestinal cancers of the:

  • stomach
  • pancreas
  • colon and rectum

Reference:

  • Cascinu, S. et al. A randomised trial of octreotide vs best supportive care only in advanced gastrointestinal cancer patients refractory to chemotherapy. Brit. J. Cancer 1995;71: 97-101.
  • Rinke, A., H.H. Muller, C. Schade-Brittinger, K.J. Klose, P. Barth, M. Wied, et al., Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol, 2009. 27(28): p. 4656-63.

Related pages

Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page